NICE launches public consultation on proposals to simplify how medicines and medical devices are selected for evaluation

For medicines, the proposals confirm commitment in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access that NICE will appraise all new active substances and significant licence extensions for existing medicines, except where there is a clear rationale not to do so.

National Institute for Health and Care Excellence